Cardinal Health’s work in the cell and gene therapies space has been recognized in the most recent Innovations Issue of PM360, an industry-leading publication that annually honors the most innovative companies, products and services in the life sciences.
This year, the publication is recognizing Cardinal Health’s newly launched Advanced Therapy Solutions service, which was created to more holistically support biopharma companies with a high-touch, coordinated customer experience by removing obstacles and delays for innovative therapies, with real-world evidence and outcomes, regulatory consulting, site-of-care logistics, order-to-cash management, and patient access and support.
“As healthcare solutions become more advanced, it was inevitable that manufacturers and biopharma companies would need to rethink how they approach the development and commercialization of these advanced therapies,” says Craig Cowman, executive vice president, Strategic Sourcing and Manufacturer Services at Cardinal Health. “Advanced Therapy Solutions builds off the work Cardinal Health is already known for in this sector, through a range of tailored solutions that empower biopharma companies to help patients access novel treatments.”
Currently, there are only about 10 cell and gene therapies (CGTs) that have been approved by the U.S. Food and Drug Association (FDA), according to the American Society of Gene & Cell Therapy. However, there are more than 3,000 of these advanced therapies in various stages of development worldwide. CGTs introduce unprecedented challenges in every stage of the lifecycle, beginning in the development stage, through manufacturing and logistics. From delivering cryogenic materials to sites of care, to specialized workforce training that can ensure the viability and safety of these products, and coordinating patient travel to treatment centers, new development heavily relies on partners in the healthcare industry – including Cardinal Health’s experts who understand and manage the complexities.
Cardinal Health has been a leader in this field from the beginning. The company has supported the launch of the first CAR-T products, has provided its expertise in regulatory support and consulting for more than 40 advanced therapies in 12 therapeutic areas, and has processed more than 8,000 cell therapy orders.
By pulling together a team of subject matter experts across businesses that have experience in CGTs, Cardinal Health is now better equipped to develop unique solutions for these unique products.
Read PM360’s article here.
Learn more about Cardinal Health’s Advanced Therapy Solutions here.